Disorders

Anorexia Nervosa

Anorexia Nervosa

An estimated 0.5 to 3.7 percent of females suffer from anorexia nervosa in their lifetime. Symptoms of anorexia nervosa include:

People with this disorder see themselves as overweight even though they are dangerously thin. The process of eating becomes an obsession. Unusual eating habits develop, such as avoiding food and meals, picking out a few foods and eating these in small quantities, or carefully weighing and portioning food. People with anorexia may repeatedly check their body weight, and many engage in other techniques to control their weight, such as intense and compulsive exercise, or purging by means of vomiting and abuse of laxatives, enemas, and diuretics. Girls with anorexia often experience a delayed onset of their first menstrual period.

The course and outcome of anorexia nervosa vary across individuals: some fully recover after a single episode; some have a fluctuating pattern of weight gain and relapse; and others experience a chronically deteriorating course of illness over many years. The mortality rate among people with anorexia has been estimated at 0.56 percent per year, or approximately 5.6 percent per decade, which is about 12 times higher than the annual death rate due to all causes of death among females ages 15-24 in the general population. The most common causes of death are complications of the disorder, such as cardiac arrest or electrolyte imbalance, and suicide.

Leave your comments

Health News

Surgeon Removes Eight Pound Liver Tumor

The cancerous tumor in Marcus Muhich's liver weighed 8 pounds and was nearly a foot across. Doctors at three major academic medical centers in the Midwest told Muhich his high-grade tumor was inoperable. Then he was referred to Dr... [ read article ]

NIPPV Linked To Increased Hospital Mortality Rates In Small Group Of Patients

Although increased use of noninvasive positive-pressure ventilation (NIPPV) nationwide has helped decrease mortality rates among patients hospitalized with chronic obstructive pulmonary disease (COPD), a small group of... [ read article ]

FDA Approves Label Update For PREZISTA® To Include 192-Week Data In HIV-1-Infected Adult Patients

Starting Treatment Janssen Therapeutics, Division of Janssen Products, LP, announced that the U.S. Food and Drug Administration (FDA) has approved a label update for PREZISTA® (darunavir) tablets to include 192-week data from the ARTEMIS study... [ read article ]

Recommended Stuff

Our Latest Blog Entries...